Breaking News

WellSpring Appoints BD Executive and Technical Director

By Kristin Brooks | February 3, 2014

Barish and Watt bring extensive pharmaceutical experience

Lonnie Barish has been appointed executive director of business development at WellSpring Pharma Services, and David Watt has been named technical director of Pharma Services.
Mr. Watt has more than 20 years of pharmaceutical GMP experience in technical definition and evaluation of contract development and manufacturing projects from both the provider and client side. Mr. Watt previously held positions with Valeant, Medicis, Patheon and Syntex Pharmaceuticals.
Mr. Barish has more than 20 years of experience in pharmaceutical sales, marketing and business development. Most recently he served as executive director, North America, at Nuvisan, and business development director at CoreLab Partners and AAIPharma Services Corp.
“David and Lonnie both bring extensive industry experience and have outstanding reputations within the industry,” said Sam Ricchezza, vice president, business development. “I am excited to have these two outstanding individuals on board to help us continue building upon our leadership position in the global pharmaceutical manufacturing services business.”
"We are excited with the additions of these two key appointments to the WellSpring Pharma Services team." said Wendy Shusko, president of WellSpring Pharmaceutical Corp. “Lonnie and David bring a great deal of business development experience and technical knowledge to our company and will no doubt have a tremendous impact on our company as we grow our business."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important